NCT03595488View on ClinicalTrials.gov

Dupilumab for Aspirin-exacerbated Respiratory Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 5, 2018

Primary Completion Date

December 11, 2019

Study Completion Date

December 11, 2019

Conditions
Aspirin-exacerbated Respiratory Disease
Interventions
DRUG

Dupilumab

dupilumab 300 mg subcutaneous injection every 2 weeks

Trial Locations (1)

14607

Rochester Regional Health - Allergy/Immunology, Rochester

All Listed Sponsors
lead

Rochester General Hospital

OTHER

NCT03595488 - Dupilumab for Aspirin-exacerbated Respiratory Disease | Biotech Hunter | Biotech Hunter